HALEOS LABS Latest Share Price (HALEOSLABS)
TODAY IN ONE LINE
HALEOSLABS fell 2.1%, lagging Nifty's 0.1% move.
With a market cap of ₹443.21 Cr., it trades at a P/E of N/A. Track live valuations, technical indicators, and peers comparison below. Check delivery conviction and recent filings to build your view.
How good is this company?
Overall performance across 5 key dimensions.
HALEOS LABS flags & news
Key strengths, potential risks, and recent updates.
Green Flags
- ●High Promoter HoldingPromoters hold 72.1% skin-in-the-game
- ●Zero Pledge RiskNo recent active promoter pledging found
Red Flags
- ●Sales ContractionQuarterly sales dropped 7.0% YoY
- ●Poor Capital ReturnsLow ROE of 8.3%
Latest HALEOS LABS News
What changed recently?
Recent events, corporate actions, and announcements.
HALEOS LABS valuation: P/E, P/B and sector benchmarks.
Twelve years of multiples investors have paid for HALEOS LABS, framed against the sector median so the premium or discount is obvious at a glance.
Market-priced ratios use the latest available quote; accounting metrics use the latest reported filing. Compare values with matched peers and the company's own history.
Valuation
Profitability
Growth
Financial Health
HALEOS LABS technical analysis: indicators, pivots and CPR.
Latest RSI, MACD and moving-average signals plus the latest pivot and Central Pivot Range levels for HALEOS LABS — derived from the latest tape, not yesterday's close.
HALEOS LABS last traded at ₹1,451.3 with an intraday range of ₹1,441–₹1,509.4 — latest indicator, pivot and CPR signals below.
Pivot points
Standard pivot — most widely referenced.
Pivot levels · Classic
Last: ₹1451.30| Level | Price (₹) | Distance | % Δ |
|---|---|---|---|
| R4 | 1630.27 | +178.97 | +12.33% |
| R3 | 1561.87 | +110.57 | +7.62% |
| R2 | 1535.63 | +84.33 | +5.81% |
| R1 | 1493.47 | +42.17 | +2.91% |
| PIVOT | 1467.23 | 15.93 | 1.10% |
| CURRENT | 1451.30 | — | — |
| S1 | 1425.07 | -26.23 | -1.81% |
| S2 | 1398.83 | -52.47 | -3.62% |
| S3 | 1356.67 | -94.63 | -6.52% |
| S4 | 1288.27 | -163.03 | -11.23% |
HALEOSLABS is trading Below CPR, indicating Bearishness
CPR is Wider, suggesting unlikely for trending moves
Day's range: ₹1475–₹1512.9
Trading Below opening range, showing Bearishness
HALEOS LABS financials: P&L, balance sheet, cash flow, ratios.
Reported annual and quarterly results for HALEOS LABS — consolidated or standalone — with margins, YoY growth and key ratios inline.
HALEOS LABS reports its full P&L, balance sheet, cash flow and ratios on this page — current market capitalisation of ₹443.21 Cr. and reported EPS of ₹10.71.
| Metric | Mar 2025 | Mar 2026 |
|---|---|---|
| Revenue from Operations | 345 | 334 ▼ 3.2% |
| Sales Growth YoY %Derived | 12.67% | -3.17% |
| Other Income | 5 | 2 ▼ 49.9% |
| Total Income | 350 | 336 ▼ 3.8% |
| 154 | 139 ▼ 10.1% | |
| Gross ProfitDerived | 191 | 195 ▲ 2.4% |
| Gross Margin %Derived | 55.31% | 58.50% |
| 146 | 151 ▲ 3.4% | |
| EBITDA (Operating Profit)Derived | 45 | 45 ▼ 0.8% |
| OPM %Derived | 13.07% | 13.38% |
| 24 | 22 ▼ 7.6% | |
| Profit Before Tax (PBT) | 26 | 25 ▼ 3.8% |
| 7 | 7 ▼ 0.8% | |
| Effective Tax %Derived | 28.47% | 29.35% |
| Total Profit for Period | 19 | 18 ▼ 5.0% |
| Less: Non-controlling Interests | -1 | 0 ▲ 135.5% |
| Net Profit (Owner's PAT)Derived | 20 | 17 ▼ 13.9% |
| Net Profit Margin %Derived | 5.83% | 5.19% |
| PAT Growth YoY %Derived | 121.15% | -13.91% |
| Earnings Per Share (EPS ₹) | 66.51 | 57.26 ▼ 13.9% |
| Diluted Shares Outstanding (Cr) | 0 | 0 ▲ 0.0% |
| Share of Profit from Associates/JVs | — | — |
| Other Comprehensive Income (Net of Tax) | 0 | 0 ▼ 14.9% |
| Total Expenses (incl. D&A & Interest) | 323 | 311 ▼ 3.8% |
| Material Cost % of RevenueDerived | 43.49% | 43.95% |
| Employee Cost % of RevenueDerived | 17.27% | 19.59% |
| Other Cost % of RevenueDerived | 24.97% | 25.53% |
| Interest Coverage (x)Derived | 3.45x | 4.53x |
| Period | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | Trend |
|---|---|---|---|---|---|---|---|---|---|
| Revenue from Operations | 378 | 261 ▼ 31.0% | 266 ▲ 1.8% | 350 ▲ 31.7% | 316 ▼ 9.8% | 306 ▼ 3.0% | 345 ▲ 12.7% | 334 ▼ 3.2% | |
| Sales Growth YoY %Derived | — | -30.98% | 1.84% | 31.68% | -9.77% | -3.04% | 12.67% | -3.17% | |
| Other Income | 3 | 2 ▼ 10.4% | 2 ▼ 21.9% | 2 ▲ 16.0% | 3 ▲ 48.7% | 4 ▲ 24.6% | 5 ▲ 27.0% | 2 ▼ 49.9% | |
| Total Income | 380 | 263 ▼ 30.8% | 267 ▲ 1.6% | 352 ▲ 31.6% | 319 ▼ 9.4% | 310 ▼ 2.8% | 350 ▲ 12.8% | 336 ▼ 3.8% | |
256 | 158 ▼ 38.3% | 137 ▼ 13.2% | 195 ▲ 42.1% | 171 ▼ 12.0% | 151 ▼ 11.8% | 154 ▲ 1.9% | 139 ▼ 10.1% | ||
| Gross ProfitDerived | 122 | 103 ▼ 15.6% | 129 ▲ 24.9% | 155 ▲ 20.6% | 144 ▼ 7.0% | 155 ▲ 7.4% | 191 ▲ 23.2% | 195 ▲ 2.4% | |
| Gross Margin %Derived | 32.28% | 39.46% | 48.40% | 44.33% | 45.68% | 50.59% | 55.31% | 58.50% | |
87 | 78 ▼ 11.2% | 98 ▲ 26.9% | 121 ▲ 22.9% | 115 ▼ 4.5% | 124 ▲ 7.2% | 146 ▲ 17.7% | 151 ▲ 3.4% | ||
| EBITDA (Operating Profit)Derived | 35 | 25 ▼ 26.9% | 30 ▲ 18.9% | 34 ▲ 13.2% | 29 ▼ 15.8% | 31 ▲ 8.2% | 45 ▲ 44.8% | 45 ▼ 0.8% | |
| OPM %Derived | 9.19% | 9.73% | 11.36% | 9.76% | 9.11% | 10.17% | 13.07% | 13.38% | |
12 | 13 ▲ 9.3% | 12 ▼ 4.7% | 29 ▲ 133.0% | 20 ▼ 31.0% | 25 ▲ 25.9% | 24 ▼ 5.5% | 22 ▼ 7.6% | ||
| Profit Before Tax (PBT) | 25 | 15 ▼ 42.2% | 20 ▲ 33.4% | 33 ▲ 67.3% | 17 ▼ 49.3% | 10 ▼ 40.7% | 26 ▲ 166.0% | 25 ▼ 3.8% | |
8 | 4 ▼ 40.5% | 6 ▲ 34.0% | 7 ▲ 23.6% | 5 ▼ 29.8% | 4 ▼ 32.5% | 7 ▲ 111.9% | 7 ▼ 0.8% | ||
| Effective Tax %Derived | 29.69% | 30.58% | 30.72% | 22.70% | 31.43% | 35.74% | 28.47% | 29.35% | |
| Total Profit for Period | 18 | 10 ▼ 42.9% | 14 ▲ 33.1% | 25 ▲ 86.5% | 11 ▼ 55.0% | 6 ▼ 44.4% | 19 ▲ 196.0% | 18 ▼ 5.0% | |
| Less: Non-controlling Interests | — | — | — | — | -0 | -3 ▼ 2789.2% | -1 ▲ 50.2% | 0 ▲ 135.5% | |
| Net Profit (Owner's PAT)Derived | 18 | 10 ▼ 42.9% | 14 ▲ 33.1% | 25 ▲ 86.5% | 11 ▼ 54.6% | 9 ▼ 20.7% | 20 ▲ 121.2% | 17 ▼ 13.9% | |
| Net Profit Margin %Derived | 4.72% | 3.90% | 5.10% | 7.23% | 3.64% | 2.97% | 5.83% | 5.19% | |
| PAT Growth YoY %Derived | — | -42.94% | 33.13% | 86.46% | -54.61% | -20.75% | 121.15% | -13.91% | |
| Earnings Per Share (EPS ₹) | 59.03 | 33.68 ▼ 42.9% | 44.84 ▲ 33.1% | 83.61 ▲ 86.5% | 37.92 ▼ 54.6% | 30.08 ▼ 20.7% | 66.51 ▲ 121.1% | 57.26 ▼ 13.9% | |
| Diluted Shares Outstanding (Cr) | 0 | 0 ▲ 0.0% | 0 ▲ 0.0% | 0 ▲ 0.0% | 0 ▲ 0.0% | 0 ▲ 0.0% | 0 ▲ 0.0% | 0 ▲ 0.0% | |
| Share of Profit from Associates/JVs | — | — | — | -0 | — ▲ 100.0% | — | — | — | |
| Other Comprehensive Income (Net of Tax) | -0 | -0 ▼ 1126.3% | -0 ▲ 76.5% | -0 ▲ 51.1% | 0 ▲ 167.7% | -0 ▼ 1970.0% | 0 ▲ 128.8% | 0 ▼ 14.9% | |
| Total Expenses (incl. D&A & Interest) | 355 | 248 ▼ 30.0% | 248 ▼ 0.2% | 319 ▲ 28.8% | 302 ▼ 5.3% | 300 ▼ 0.7% | 323 ▲ 7.8% | 311 ▼ 3.8% | |
| Material Cost % of RevenueDerived | 71.14% | 56.39% | 50.89% | 58.46% | 54.29% | 49.09% | 43.49% | 43.95% | |
| Employee Cost % of RevenueDerived | 6.12% | 10.19% | 11.54% | 11.41% | 13.76% | 16.10% | 17.27% | 19.59% | |
| Other Cost % of RevenueDerived | 16.97% | 19.54% | 25.50% | 23.16% | 22.81% | 24.32% | 24.97% | 25.53% | |
| Interest Coverage (x)Derived | 5.15x | 3.41x | 4.93x | 3.91x | 2.64x | 1.59x | 3.45x | 4.53x |
HALEOS LABS segment analysis : revenue and profit mix.
Disclosed business segments at HALEOS LABS with their share of revenue and profit, switchable between consolidated and standalone reporting.
HALEOS LABS discloses revenue and profit across multiple business segments — toggle between consolidated and standalone views to see the mix.
Segment-wise Financial Analysis
The Bull, Bear, and Flip case for HALEOS LABS.
Our AI distills the core fundamental drivers supporting HALEOS LABS, the risks that threaten it, and the quantitative conditions that could weaken the thesis.
What you're getting.
No strengths or opportunities on record.
Key Risks.
No weaknesses or threats on record.
Flip Conditions.
Reassess if quarterly profit growth turns negative for two consecutive quarters. The bull case relies on compounding earnings.
Watch interest coverage if debt-to-equity climbs above 1.00. Balance sheet risk re-prices growth multiples fast.
Return-quality risk. ROE below 8% would indicate weaker capital compounding.
Income thesis breaks if the dividend is cut or yield falls below 0.05%.
HALEOS LABS peer comparison — same-sector benchmarks.
Same-sector listed peers ranked on P/E, market cap, dividend yield and growth — HALEOS LABS is highlighted for quick read-across.
Quick Compare
Peer Comparison
| Company Name |
|---|
HALEOS LABS chart patterns: breakouts, tops and bottoms.
Auto-detected classical chart patterns for HALEOS LABS — Double Top/Bottom, Head & Shoulders, Triple Bottom and more — with break levels, targets and quality scores across Intraday, Daily and Weekly timeframes.
HALEOS LABS delivery volume — last 20 sessions of conviction.
Daily traded volume and delivery percentage for HALEOS LABS over 20 sessions — the gap between intraday flipping and genuine accumulation.
Latest session delivery in HALEOS LABS stood at 96.8% of traded volume, against a 20-day average of 80.1%.
HALEOS LABS announcements: results, concalls, ratings, M&A.
Filings HALEOS LABS sent to the exchanges, sequenced as they hit the tape — concall transcripts, results, credit ratings and presentations.
HALEOS LABS files concall transcripts, results, credit ratings and corporate-action notices on the NSE and BSE exchange portals — latest 72 documents below.
General Updates
HALEOS LABS LIMITED has informed the Exchange about Events Calendar (AGM)
Record Date
HALEOS LABS LIMITED has informed the Exchange that Record date for the purpose of Dividend is 23-Sep-2026.
Shareholders meeting
HALEOS LABS LIMITED has submitted the Exchange a copy Srutinizers report of Postal Ballot. Further, the company has informed the Exchange regarding…
Updates
HALEOS LABS LIMITED has informed the Exchange regarding 'Communication To Shareholders (TDS Related)'.
Copy of Newspaper Publication
HALEOS LABS LIMITED has informed the Exchange about Copy of Newspaper Publication
Investor decks & rating reports.
HALEOS LABS dividend history, splits and bonus issues.
Every dividend, stock split and bonus issue HALEOS LABS has declared, sequenced by announce and record date.
HALEOS LABS corporate-action history below covers all declared dividends, stock splits and bonus issues recorded with NSE and BSE.
About HALEOS LABS: business, sector, key facts.
What HALEOS LABS does, where it operates, the people running it, and the numbers that describe the entity behind the ticker.
HALEOS LABS is a listed Indian equity, listed as NSE: HALEOSLABS, BSE: 540679.
Related
Peers, sector trends, screeners and strategy playbooks contextual to this stock.
- AAREY DRUGS & PHARM (AAREYDRUGS) Share PricePeer
- AARTI DRUGS (AARTIDRUGS) Share PricePeer
- AARTI PHARMALABS (AARTIPHARM) Share PricePeer
- AJANTA PHARMA (AJANTPHARM) Share PricePeer
- AKUMS DRUGS AND PHARMA L (AKUMS) Share PricePeer
- Top Gainers TodayScreener
- EMA Crossover ScreenerScreener
- Stock Quality ScorecardScreener
- Technical DashboardScreener
- Results CalendarScreener
- FII Buying ActivityScreener
- All Technical ScreenersScreener
- All Trading StrategiesStrategy
Questions investors ask about HALEOS LABS (HALEOSLABS).
Quick answers grounded in this page's data — price action, fundamentals, ratios and ownership.
01What is the current share price of HALEOS LABS (HALEOSLABS)?
The current share price of HALEOS LABS (HALEOSLABS) is ₹1,451.30. Today, the stock has declined by ₹30.80 (2.08%), trading in a range of ₹1,441.00 to ₹1,509.40. The stock opened at ₹1,509.40 with a trading volume of 5,164 shares.
02Is HALEOS LABS stock a good investment for long-term?
HALEOS LABS can be considered for long-term investment based on several factors. The company has a market capitalization of ₹443.21 Cr., P/E ratio of 0, ROE of 8.28%, and ROCE of 7.15%. The dividend yield stands at 0.1%. However, investment decisions should be based on your financial goals, risk appetite, and thorough research. It's recommended to consult with a SEBI-registered financial advisor before making investment decisions.
03What is the 52-week high and low price of HALEOS LABS stock?
The 52-week high price of HALEOS LABS (HALEOSLABS) is ₹1,774.00, while the 52-week low is ₹1,181.00. Currently trading at ₹1,451.30, the stock is 22.89% above its 52-week low and 18.19% below its 52-week high. These levels help investors understand the stock's price volatility and trading range over the past year.
04Should I buy HALEOS LABS stock at the current price?
Whether to buy HALEOS LABS stock at ₹1,451.30 depends on multiple factors. The stock is currently trading with a P/E ratio of 0 and P/B ratio of 0. Today's performance shows a loss of 2.08%. Consider analyzing the company's fundamentals, technical indicators, industry trends, and your investment horizon. Compare these metrics with industry peers and consult a financial advisor for personalized advice.
05What is the dividend yield of HALEOS LABS and when is the next dividend?
HALEOS LABS offers a dividend yield of 0.1%, which means for every ₹100 invested at the current price of ₹1,451.30, you can expect to receive approximately ₹0.10 annually as dividends. The face value of the stock is ₹10.00. For information about the next dividend announcement and ex-dividend date, please check the company's official announcements or visit the BSE/NSE websites.
06What are the key financial ratios and metrics of HALEOS LABS?
HALEOS LABS's key financial metrics include: P/E Ratio: 0, P/B Ratio: 0, ROE: 8.28%, ROCE: 7.15%, Dividend Yield: 0.1%, EPS: ₹10.71, Book Value: ₹759.29, and Debt-to-Equity: 0.43. The company's market cap stands at ₹443.21 Cr.. These metrics help evaluate the company's valuation, profitability, and financial health.
07How is HALEOS LABS stock performing today in the market?
HALEOS LABS stock opened at ₹1,509.40 and is currently trading at ₹1,451.30, showing a decline of ₹30.80 (2.08%). The intraday high is ₹1,509.40 and low is ₹1,441.00. The trading volume stands at 5,164 shares, indicating moderate market participation today.
08What is the P/E ratio of HALEOS LABS and what does it indicate?
HALEOS LABS has a Price-to-Earnings (P/E) ratio of 0, which means investors are willing to pay 0.00 for every ₹1 of earnings. With an EPS of ₹10.71, this P/E ratio suggests the stock may be undervalued or facing growth challenges. Compare this with industry peers and historical P/E ratios for better context.
The data, ratios and commentary about HALEOS LABS (HALEOSLABS) on this page are published for educational and informational purposes only and are not investment, legal or tax advice. StockeZee is not a SEBI-registered investment adviser, research analyst or portfolio manager, and no content here should be construed as a recommendation to buy, hold or sell any security. Live and historical market data may be delayed, revised by the exchanges, or contain errors; figures sourced from third-party feeds and corporate disclosures may not always be current. Past performance is not indicative of future results, and equity investments carry the risk of capital loss. Before acting on anything you read here, please consult a SEBI-registered financial advisor and read all scheme-related documents carefully.